$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000117184319007384 Filed on November 08, 2019

Income Statement

Concept	2019 Q3	2018 Q4	2018 Q3
Revenue	$1.775M	$2.729M	$1.454M
YoY Change	22.08%	-29.85%	-83.4%
Cost Of Revenue	$0.00	$70.00K
YoY Change		-46.15%
Gross Profit	$1.775M	$2.660M	$1.454M
YoY Change	22.08%	-29.26%	-80.91%
Gross Profit Margin	100.0%	97.47%	100.0%
Selling, General & Admin	$11.74M	$4.190M	$7.923M
YoY Change	48.11%	-10.85%	137.0%
% of Gross Profit	661.13%	157.52%	544.91%
Research & Development	$25.12M	$23.43M	$22.01M
YoY Change	14.15%	38.48%	25.68%
% of Gross Profit	1415.21%	880.83%	1513.48%
Depreciation & Amortization	$180.0K	$200.0K	$190.0K
YoY Change	-5.26%	11.11%	5.56%
% of Gross Profit	10.14%	7.52%	13.07%
Operating Expenses	$36.86M	$27.62M	$29.93M
YoY Change	23.14%	27.75%	43.53%
Operating Profit	-$35.10M	-$24.96M	-$28.49M
YoY Change	23.18%	39.75%	113.45%
Interest Expense	$3.044M	-$2.170M	$2.346M
YoY Change	29.75%	29.17%	9.63%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$37.59M	-$27.43M	-$29.60M
YoY Change	26.99%	40.38%	95.64%
Income Tax
% Of Pretax Income
Net Earnings	-$37.59M	-$27.43M	-$29.60M
YoY Change	27.01%	40.37%	95.57%
Net Earnings / Revenue	-2117.86%	-1005.2%	-2035.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$340.4K	-$249.6K	-$280.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding	110.4M		105.4M

Balance Sheet

Concept	2019 Q3	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.44M	$104.5M	$120.3M
YoY Change	-43.12%	-8.68%	-25.55%
Cash & Equivalents	$29.90M	$26.73M	$52.58M
Short-Term Investments	$38.53M	$77.74M	$67.74M
Other Short-Term Assets	$4.900M	$4.000M	$3.900M
YoY Change	25.64%	-18.37%	-17.02%
Inventory	$1.776M	$1.649M	$821.0K
Prepaid Expenses
Receivables	$3.598M	$4.293M	$3.394M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$78.80M	$114.4M	$128.5M
YoY Change	-38.67%	-8.8%	-26.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.452M	$9.135M	$9.236M
YoY Change	-19.32%	-4.31%	-3.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$22.40M	$29.20M
YoY Change	-100.0%	-45.76%	548.89%
Other Assets	$4.245M	$978.0K	$1.420M
YoY Change	198.94%	-51.75%	-27.37%
Total Long-Term Assets	$11.70M	$32.49M	$39.81M
YoY Change	-70.62%	-38.55%	146.95%
TOTAL ASSETS
Total Short-Term Assets	$78.80M	$114.4M	$128.5M
Total Long-Term Assets	$11.70M	$32.49M	$39.81M
Total Assets	$90.50M	$146.8M	$168.3M
YoY Change	-46.23%	-17.62%	-12.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.08M	$7.769M	$7.911M
YoY Change	27.47%	22.6%	71.87%
Accrued Expenses	$24.95M	$15.89M	$15.12M
YoY Change	65.04%	25.14%	27.37%
Deferred Revenue
YoY Change
Short-Term Debt	$29.50M	$29.10M	$29.00M
YoY Change	1.72%	1.39%	1.4%
Long-Term Debt Due	$4.000M	$4.600M	$1.700M
YoY Change	135.29%	-29.23%	-64.58%
Total Short-Term Liabilities	$82.17M	$69.48M	$64.36M
YoY Change	27.68%	-7.16%	-7.05%
LONG-TERM LIABILITIES
Long-Term Debt	$46.00M	$28.10M	$31.00M
YoY Change	48.39%	44.1%	46.92%
Other Long-Term Liabilities	$3.543M	$2.703M	$100.0K
YoY Change	3443.0%	1251.5%	-80.0%
Total Long-Term Liabilities	$3.543M	$2.703M	$31.10M
YoY Change	-88.61%	-86.28%	43.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$82.17M	$69.48M	$64.36M
Total Long-Term Liabilities	$3.543M	$2.703M	$31.10M
Total Liabilities	$85.71M	$72.18M	$95.40M
YoY Change	-10.16%	-23.62%	4.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$838.0M	-$732.0M	-$704.5M
YoY Change	18.94%	15.85%	15.06%
Common Stock	$1.104M	$1.101M	$1.096M
YoY Change	0.73%	11.89%	11.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$41.25M	$49.24M	$72.87M
YoY Change
Total Liabilities & Shareholders Equity	$90.50M	$146.8M	$168.3M
YoY Change	-46.23%	-17.62%	-12.11%

Cashflow Statement

Concept	2019 Q3	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$37.59M	-$27.43M	-$29.60M
YoY Change	27.01%	40.37%	95.57%
Depreciation, Depletion And Amortization	$180.0K	$200.0K	$190.0K
YoY Change	-5.26%	11.11%	5.56%
Cash From Operating Activities	-$27.64M	-$23.99M	-$35.03M
YoY Change	-21.1%	128.04%	181.82%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$110.0K	-$40.00K
YoY Change	100.0%	-8.33%	-78.95%
Acquisitions
YoY Change
Other Investing Activities	$23.60M	-$3.070M	-$9.480M
YoY Change	-348.95%	-94.49%	-315.95%
Cash From Investing Activities	$23.51M	-$3.170M	-$9.520M
YoY Change	-346.95%	-94.32%	-326.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$53.40M
YoY Change			-38.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	190.0K	1.330M	63.92M
YoY Change	-99.7%	133.33%	-25.94%
NET CHANGE
Cash From Operating Activities	-27.64M	-23.99M	-35.03M
Cash From Investing Activities	23.51M	-3.170M	-9.520M
Cash From Financing Activities	190.0K	1.330M	63.92M
Net Change In Cash	-3.940M	-25.83M	19.37M
YoY Change	-120.34%	-60.72%	-75.19%
FREE CASH FLOW
Cash From Operating Activities	-$27.64M	-$23.99M	-$35.03M
Capital Expenditures	-$80.00K	-$110.0K	-$40.00K
Free Cash Flow	-$27.56M	-$23.88M	-$34.99M
YoY Change	-21.23%	129.62%	185.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2723000
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	1000
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	152000
CY2019Q3	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	250000
CY2018Q4	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	444000
CY2019Q3	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
CY2018Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	22376000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-144000
CY2019Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	3741000
CY2019Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive	428000
CY2019Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	5577000
CY2019Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	6981000
CY2019Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	8976000
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	-56000
CY2017Q4	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	200000000
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10084000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7769000
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3598000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4293000
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24954000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15938000
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	60000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-297000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS INC
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Trading Symbol TradingSymbol	bcrx
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	38532000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	100112000
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	795589000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	780400000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3317000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5385000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5329000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2903000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2084000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2085000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14031000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7072000
CY2019Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	341000
CY2018Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	222000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	936000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	676000
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	541
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2475
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1892
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2071
CY2019Q3	us-gaap	Assets Assets	90500000
CY2018Q4	us-gaap	Assets Assets	146841000
CY2019Q3	us-gaap	Assets Current AssetsCurrent	78803000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	114352000
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	67000
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	316000
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	38222000
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	99965000
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	38532000
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	77736000
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	38532000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	77736000
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	22376000
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29903000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26731000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31450000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3175000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522000
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28275000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53568000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110438000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110063000
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110438000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110063000
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	1104000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1101000
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37573000
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29555000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105918000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73987000
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1399000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	36873000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	29947000
	us-gaap	Costs And Expenses CostsAndExpenses	108456000
	us-gaap	Costs And Expenses CostsAndExpenses	86882000
CY2018Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	238000
CY2017Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1126000
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	54000
CY2019Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	221000
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	221000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	539000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	572000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	25703000
CY2019Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	148000
CY2018Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	631000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	331000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	334000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9975000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3947000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7100000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-532000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-606000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1575000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1668000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	127000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	821000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1018000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1063000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-695000
CY2019Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	402000
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	611000
	us-gaap	Interest And Other Income InterestAndOtherIncome	1545000
	us-gaap	Interest And Other Income InterestAndOtherIncome	1566000
CY2019Q3	us-gaap	Interest Expense InterestExpense	3044000
CY2018Q3	us-gaap	Interest Expense InterestExpense	2346000
	us-gaap	Interest Expense InterestExpense	8805000
	us-gaap	Interest Expense InterestExpense	6762000
CY2019Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	3042000
CY2018Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2346000
	us-gaap	Interest Expense Debt InterestExpenseDebt	8803000
	us-gaap	Interest Expense Debt InterestExpenseDebt	6762000
CY2019Q3	us-gaap	Interest Payable Current InterestPayableCurrent	13423000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	11848000
CY2019Q3	us-gaap	Inventory Net InventoryNet	1776000
CY2018Q4	us-gaap	Inventory Net InventoryNet	1649000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11226000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7765000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	512000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	519000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	580000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1450000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	400000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6231000
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90500000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	146841000
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	82169000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69477000
CY2019Q3	us-gaap	Line Of Credit LineOfCredit	46041000
CY2018Q4	us-gaap	Line Of Credit LineOfCredit	25372000
CY2019Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4036000
CY2018Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4580000
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	50000000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20000000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7935000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79136000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68580000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20638000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61167000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61673000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-31054000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37629000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-37592000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-25777000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-18446000
	us-gaap	Net Income Loss NetIncomeLoss	-106275000
	us-gaap	Net Income Loss NetIncomeLoss	-73820000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-29597000
CY2019Q3	us-gaap	Notes Payable Current NotesPayableCurrent	29451000
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	29121000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35098000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28493000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-99346000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-68958000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1064000
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4995000
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4245000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	978000
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	208000
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	130000
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	19000
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-233000
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	24000
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	42000
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	42000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	357000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-167000
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3543000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2703000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3018000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	43158000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	263000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	262000
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3447000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2399000
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53400000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53400000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	19477000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	10353000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	64954000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	51355000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1161000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1495000
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7452000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9135000
CY2019Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	3598000
CY2018Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	4293000
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	1000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4025000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25120000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22006000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80294000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61457000
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1547000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1544000
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838006000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-731969000
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1775000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1454000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9110000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17924000
CY2019Q3	us-gaap	Royalty Expense RoyaltyExpense	18000
CY2018Q3	us-gaap	Royalty Expense RoyaltyExpense	18000
	us-gaap	Royalty Expense RoyaltyExpense	131000
	us-gaap	Royalty Expense RoyaltyExpense	401000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26632000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25024000
	us-gaap	Share Based Compensation ShareBasedCompensation	14031000
CY2018Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	164000
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53400000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	343000
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	414000
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81000
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	468000
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	595000
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11735000
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7923000
	us-gaap	Share Based Compensation ShareBasedCompensation	7072000
CY2018Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.50
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10455000
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	220000
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	184000
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	187000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-41253000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	49235000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	22507000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-9193000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	83767000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	62054000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	46184000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	72873000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 31.9pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 34.1pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Actual results could differ from those estimates.</div></div></div>
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110416000
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105410000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110308000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100955000

Files In Submission

Name	View Source	Status
0001171843-19-007384-index-headers.html	Edgar Link	pending
0001171843-19-007384-index.html	Edgar Link	pending
0001171843-19-007384.txt	Edgar Link	pending
0001171843-19-007384-xbrl.zip	Edgar Link	pending
bcrx-20190930.xml	Edgar Link	completed
bcrx-20190930.xsd	Edgar Link	pending
bcrx-20190930_cal.xml	Edgar Link	unprocessable
bcrx-20190930_def.xml	Edgar Link	unprocessable
bcrx-20190930_lab.xml	Edgar Link	unprocessable
bcrx-20190930_pre.xml	Edgar Link	unprocessable
exh_101.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_110819p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2019 Q3 Form 10-Q Financial Statement

#000117184319007384 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2019 Q3 Form 10-Q Financial Statement

#000117184319007384 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx